Compare ORIC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORIC | PHAR |
|---|---|---|
| Founded | 2014 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 793.4M |
| IPO Year | 2020 | 2020 |
| Metric | ORIC | PHAR |
|---|---|---|
| Price | $12.38 | $10.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 3 |
| Target Price | $19.73 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 1.1M | 15.9K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.04 |
| Revenue Next Year | N/A | $2.51 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.23 | $9.62 |
| 52 Week High | $14.93 | $21.34 |
| Indicator | ORIC | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 45.46 | 38.38 |
| Support Level | $10.67 | $9.62 |
| Resistance Level | $12.57 | $13.51 |
| Average True Range (ATR) | 0.59 | 0.40 |
| MACD | -0.19 | -0.05 |
| Stochastic Oscillator | 20.92 | 5.87 |
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.